Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-inflammatory Agent
Anti-inflammatory agent 105 targets the inhibition of TNF-α synthesis and release, demonstrating a potent biological activity with an IC50 of 0.124 nM in the human macrophage cell line U937. This compound is valuable for research applications focused on understanding inflammation-related pathways and the development of therapeutic strategies against inflammatory diseases. -
TNFα/IL-2 Inhibitor
Immuno modulator-1 is a potent inhibitor of TNFα and IL-2, displaying IC50 values of 4.7 nM and 26 nM, respectively, in human peripheral blood mononuclear cells (hPBMC). This compound is valuable for investigating immune response modulation and inflammatory pathways. Additionally, Immuno modulator-1 demonstrates a hERG potassium channel blocking effect, exhibiting a 20% inhibitory percentage at a concentration of 3 μM, making it relevant for studies involving cardiac safety profiles. -
TLR7 Agonist
SMU-L11-R is a selective TLR7 agonist that demonstrates an EC50 of 0.012 μM for human TLR7. This compound specifically activates TLR7, recruits MyD88, and initiates the MAPK/NF-κB signaling pathways, resulting in the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in both mouse and human peripheral blood mononuclear cells. Additionally, SMU-L11-R promotes M1-like macrophage polarization and exhibits synergistic anti-tumor effects in combination with PD-L1 inhibitors through the upregulation of CD8+ T cells, making it a valuable tool for research in colorectal cancer. -
Anti-inflammatory Agent
Sinulatumolin C is an anti-inflammatory agent that exhibits significant inhibition of tumor necrosis factor-alpha (TNF-α), with an IC50 value of 2.6 μM. This compound is valuable for research applications focused on understanding inflammatory pathways and exploring potential therapeutic strategies for inflammatory diseases. Its efficacy in modulating TNF-α makes it a useful tool in the study of immune responses and related biological processes. -
Anti-inflammatory Agent
Kaempferol 3-O-(2G-glucosylrutinoside)-7-O-glucoside is a potent anti-inflammatory agent that targets key signaling pathways, including NF-κB, MAPK, and Akt. This compound significantly reduces the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2) in LPS-induced RAW 264.7 macrophages. Additionally, it suppresses the secretion of pro-inflammatory cytokines, including TNF-α, IL-1β, and IL-6, making it valuable for research into inflammation and related disorders. -
Anti-inflammatory Agent
TNF-α-IN-12 is a potent inhibitor of tumor necrosis factor-alpha (TNF-α) with an IC50 value of 0.1 μM. This compound effectively reduces TNF-α levels in serum, demonstrating anti-inflammatory activity. It is suitable for research applications aimed at understanding inflammation-related diseases and evaluating potential therapeutic strategies targeting TNF-α signaling pathways. -
COX-1/2 Inhibitor
Cudraflavone B is a prenylated flavonoid that functions as a dual inhibitor of COX-1 and COX-2, demonstrating significant anti-inflammatory and anti-tumor activity. This compound inhibits the translocation of nuclear factor κB (NF-κB) in macrophages, leading to decreased tumor necrosis factor α (TNFα) gene expression and secretion. Additionally, Cudraflavone B induces the mitochondrial apoptotic pathway while activating MAPK signaling pathways, including p38 and ERK, and upregulating SIRT1 expression. These mechanisms contribute to its efficacy in attenuating the growth of human oral squamous cell carcinoma cells, making it a valuable tool for cancer research. -
Anti-TNFRSF17/CD3E Antibody
Gamgertamig is a humanized IgG4 bispecific antibody that simultaneously targets TNFRSF17 and CD3E. This antibody exhibits potent immunomodulatory activity by activating T cells in the presence of TNFRSF17-expressing cells, making it a valuable tool for enhancing anti-tumor immune responses. It is ideal for research applications in cancer immunotherapy and provides insights into T cell modulation and tumor microenvironment interactions. -
Anti-inflammatory Agent
rel-Cleroindicin F is an anti-inflammatory agent that targets the NF-κB signaling pathway. It effectively inhibits the production of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-α) by downregulating NF-κB and its kinases in LPS-stimulated RAW 264.7 cells. This mechanism contributes to the suppression of inducible nitric oxide synthase expression, leading to decreased NO production. Rel-Cleroindicin F is valuable for research into inflammatory processes and potential therapeutic applications. -
Anti-inflammatory Agent
SKF 104351 is an orally active anti-inflammatory agent that functions by inhibiting the production of tumor necrosis factor-alpha (TNF-α). This compound plays a significant role in modulating inflammatory responses, making it valuable for research focused on chronic inflammatory diseases. Its ability to suppress cytokine production positions SKF 104351 as a crucial tool for studies aimed at understanding the mechanisms underlying inflammation and developing therapeutic interventions. -
Anti-inflammatory Agent
Arucadiol is a rosane-type diterpenoid known for its anti-inflammatory properties. It effectively inhibits the production of pro-inflammatory cytokines, specifically TNF-α, IL-1β, and IL-8, by 39.8%, 44.4%, and 34.5% respectively at a concentration of 5 μM. This compound functions by reducing the mRNA and protein expression of these inflammatory mediators, making it a valuable tool for research on inflammation-related cardiovascular conditions, such as atherosclerosis. Arucadiol can be naturally sourced from the roots of Salvia miltiorrhiza var. alba. -
Anti-Inflammatory Agent
Sinulatumolin E is a terpenoid that functions as an anti-inflammatory agent, primarily through its ability to inhibit TNF-α, with an IC50 value of 3.6 μM. This compound exhibits notable anti-inflammatory activity, making it potentially useful for research in inflammation-related pathways and conditions. -
Anti-inflammatory Agent
Trigraecum is a flavonoid compound derived from Dracaena steudneri and Dalbergia cochinchinensis, functioning as an anti-inflammatory agent. It effectively inhibits lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines such as IL-1β, IL-2, GM-CSF, and TNF-α in human peripheral blood mononuclear cells. Trigraecum is valuable for studies focused on inflammatory diseases and the underlying mechanisms of immune response modulation. -
CD28 Inhibitor
CD28-IN-3 is a selective CD28 inhibitor that effectively interrupts the CD28-B7 interaction, with an IC50 of 7.80 μM and a Kd of 52.45 μM. This compound significantly suppresses the production of key proinflammatory cytokines, including IFN-γ, IL-2, and TNF-α. CD28-IN-3 is valuable for research focused on checkpoint-resistant cancers, providing insights into immune modulation and potential therapeutic strategies. -
Anti-inflammatory Agent
Anti-inflammatory agent 11 targets and inhibits key inflammatory processes by suppressing inducible nitric oxide synthase (iNOS) expression. This compound demonstrates significant antimycobacterial activity against Mycobacterium tuberculosis strains H37Rv and M299, with minimum inhibitory concentrations (MIC50) of 1.3 μM and 6.9 μM, respectively. Additionally, it effectively reduces the production of pro-inflammatory cytokines such as TNF-α and IL-1β. Anti-inflammatory agent 11 is suitable for research in tuberculosis and related inflammatory diseases. -
Anti-inflammatory Agent
Etiprednol dicloacetate is an anti-inflammatory agent that effectively inhibits eosinophil accumulation. This compound is valuable in the study of inflammatory airway diseases, including asthma, providing insights into potential therapeutic strategies. Its mechanism of action and biological activity render it a useful tool for researchers investigating respiratory inflammation. -
Anti-inflammatory Agent
Anti-inflammatory agent 41 is an effective inhibitor of lipopolysaccharide (LPS)-induced expression of pro-inflammatory cytokines IL-6 and TNF-α in J774A.1, THP-1, and LX-2 cells. This compound also inhibits the activation of the NF-κB signaling pathway. Its primary applications include investigating the mechanisms of inflammation and assessing potential therapeutic strategies in inflammation-related diseases. -
Anti-Cancer/Inflammatory Agent
Crocatin B is a natural compound derived from P. crocatum Ruiz & Pav that functions as an anti-cancer and anti-inflammatory agent. It exerts its anti-inflammatory effects by inhibiting the expression of TNF-α and ICAM-1. Additionally, Crocatin B demonstrates notable anti-tumor activity, making it a valuable reagent for research in cancer therapies and inflammation studies. -
Anti-inflammatory Agent
Anti-inflammatory agent 20 is a potent inhibitor of nitric oxide (NO) activity, demonstrating significant anti-inflammatory properties. This compound effectively suppresses lipopolysaccharide (LPS)-induced inflammation by inhibiting the activation of NF-κB and MAPK signaling pathways, leading to a reduction in pro-inflammatory cytokines such as IL-6, TNF-α, as well as the enzymes iNOS and COX-2. It serves as a valuable tool for research applications focused on inflammation and related signaling mechanisms. -
CD28 Inhibitor
CD28-IN-1 is a selective inhibitor of CD28 with a dissociation constant (KD) of 12.48 μM. It effectively disrupts the CD28-B7 interactions, leading to a significant reduction in CD28-mediated immune activation. This compound has been shown to suppress cytokine production, including IFN-γ, IL-2, and TNF-α, in primary human T cells when co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 is suitable for research focused on tumor immunity and T cell modulation. -
Diterpenoid
Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a Kd value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis. -
COX Inhibitor
Oxaprozin is a potent, orally active cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 2.2 μM for human platelet COX-1 and 36 μM for IL-1-stimulated human synovial cell COX-2. This compound exhibits significant anti-inflammatory activity and is known to inhibit the activation of NF-κB, promoting cell apoptosis. The inhibition of the Akt/IKK/NF-κB signaling pathway is a key mechanism underlying its anti-inflammatory properties, making Oxaprozin valuable for research in inflammation and related disorders. -
Dual COX-2/EGFR Inhibitor
Melafolone is a potent dual inhibitor of COX-2 and EGFR, displaying IC50 values of 13.2 μM for COX-2 and 17.4 μM for EGFR. This compound enhances the efficacy of anti-PD-1 therapy by promoting vascular normalization and downregulating PD-L1 through the PI3K/Akt signaling pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone is suitable for applications in lung cancer research. -
Anti-inflammatory Agent
Antcin K is a selective inhibitor targeting multiple signaling pathways, including PI3K/Akt, NF-κB, MEK1/2-ERK, p38, and AP-1. It upregulates IL-10 expression, effectively inhibiting pro-inflammatory factor production, reducing monocyte adhesion, and minimizing tissue damage, while promoting myogenesis. Antcin K exhibits robust anti-inflammatory and tissue protective properties, making it valuable for research applications related to inflammation-associated diseases such as periodontitis, rheumatoid arthritis, and skeletal muscle injury. -
Nrf2/HO-1 Activator
Nrf2/HO-1 activator 2 is a difluoro-substituted compound that functions as a potent activator of the Nrf2/HO-1 signaling pathway. It exhibits neuroprotective and antioxidant properties by promoting the phosphorylation of ERK1/2, JNK, and Akt, particularly in PC12 cells. This compound is valuable for research on neurodegenerative conditions, including Parkinson's disease. -
COX Inhibitor
Oxaprozin potassium is a potent cyclooxygenase (COX) inhibitor, demonstrating IC50 values of 2.2 μM for human platelet COX-1 and 36 μM for IL-1-stimulated human synovial cell COX-2. It not only exhibits anti-inflammatory activity but also inhibits the activation of NF-κB, inducing cell apoptosis. The inhibition of the Akt/IKK/NF-κB pathway is a key mechanism contributing to its anti-inflammatory effects, making it a valuable tool for research in inflammation and related cellular processes. -
Anti-inflammatory Agent
Secologanic acid is a secoiridoid glycoside that acts as an anti-inflammatory agent. It inhibits nitric oxide (NO) production and modulates the expression of AKT and phosphorylated AKT (p-AKT). This compound demonstrates significant anti-inflammatory activity, making it valuable for research in chronic inflammatory conditions and related therapeutic applications. -
Anti-CXCR4 Antibody
LY-2624587 is a humanized IgG4 monoclonal antibody that antagonizes CXCR4. By blocking the interaction between SDF-1 and CXCR4, it inhibits SDF-1-induced GTP binding, significantly reducing cell migration and promoting apoptosis in human lymphoma and leukemia cells. Additionally, LY-2624587 impedes CXCR4 and SDF-1-mediated signaling pathways, including the activation of MAPK and AKT. This reagent is valuable for research applications involving human hematological malignancies, particularly acute myeloid leukemia (AML). -
CXCR4 Antagonist.
BPRCX807 is a selective and potent antagonist of the CXC chemokine receptor type 4 (CXCR4). It effectively inhibits CXCL12-mediated phosphorylation of ERK and Akt, leading to significant suppression of primary tumor growth. This compound is applicable for research in hepatocellular carcinoma, providing insights into its therapeutic potential in cancer treatment. -
PD-1/PD-L1 Inhibitor
PD-1/PD-L1-IN-54 is an inhibitor of the PD-1/PD-L1 interaction, targeting immune checkpoints critical for tumor immune evasion. With a KD of 55.8 μM for PD-1 and 46.4 μM for PD-L1, and an IC50 of 88.6 μM, this compound enhances CD8+ T cell activation and promotes the secretion of key cytokines such as IFN-γ and IL-2. Furthermore, PD-1/PD-L1-IN-54 exhibits anticancer properties by inhibiting tumor cell proliferation and inducing apoptosis, while also modulating T cell immunity via the PI3K/Akt signaling pathway. -
TLR2 Agonist
Pam2CSK4 is a TLR2 agonist that activates immune signaling pathways, leading to the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) in macrophage cell lines through TBK1 and MyD88. This compound stimulates the NF-κB and Bruton's tyrosine kinase pathways in platelets, enhancing interactions between platelets and endothelial cells. Pam2CSK4 promotes the expansion of myeloid-derived suppressor cells (MDSCs) and can suppress anti-tumor immune responses in the tumor microenvironment. Its applications span various diseases, including thromboinflammatory conditions, sepsis, atherosclerosis, and certain cancers, making it a valuable tool in immunological and therapeutic research. -
IL-13 Inhibitor
IL13Rα2 D1 is a potent inhibitor of the IL-13/IL13Rα2 signaling pathway. It effectively suppresses IL-13-induced cellular processes, including adhesion, migration, invasion, and proliferation. Additionally, IL13Rα2 D1 inhibits the phosphorylation of key signaling proteins such as FAK, Src, AKT, and ERK1/2, as well as the expression of matrix metalloproteinases (MMPs). This compound is valuable for research focused on cancer biology, particularly in the context of colorectal cancer. -
CXCR4 Inhibitor
Hit 14 is a selective inhibitor of C-X-C chemokine receptor type 4 (CXCR4), demonstrating an IC50 value of 254 nM. This compound effectively inhibits the migration and invasion of MDA-MB-231 cells, highlighting its potential in cancer research. Furthermore, Hit 14 modulates Akt phosphorylation and exhibits anti-inflammatory properties, demonstrating efficacy in reducing ear swelling and damage in mouse models. Its diverse biological activities make it a valuable tool for studies related to cancer metastasis and inflammation. -
COX-2 Inhibitor
Withangulatin A is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating significant potential in the modulation of inflammatory and tumorigenic processes. This compound also interferes with the MAPK, NF-κB, and Akt/mTOR/p70S6K signaling pathways, thereby exhibiting notable antitumor and anti-inflammatory activities. Additionally, Withangulatin A has been shown to possess trypanocidal effects, making it useful for research in cancer, inflammation, and parasitic diseases. -
Anti-inflammatory Agent
Oleanolic acid 28-O-β-D-glucopyranoside, a pentacyclic triterpenoid, primarily acts as an anti-inflammatory agent. It has demonstrated the ability to inhibit inflammatory responses in ulcerative colitis models, enhance intestinal epithelial barrier function, and modulate gut microbiota. The compound's mechanism involves the modulation of the PI3K-AKT and MAPK signaling pathways. Oleanolic acid 28-O-β-D-glucopyranoside is valuable for research into inflammatory diseases, particularly colitis. -
PI3K/Akt/mTOR signaling pathway Inhibitor, TLR4 signaling Inhibitor
25(R,S)-Ruscogenin is a potent inhibitor of the PI3K/Akt/mTOR and TLR4 signaling pathways. This compound effectively suppresses hepatocellular carcinoma (HCC) metastasis by decreasing the expression of matrix metalloproteinases (MMP-2 and MMP-9), uPA, VEGF, and HIF-1α. Additionally, 25(R,S)-Ruscogenin mitigates LPS-induced apoptosis in pulmonary endothelial cells, highlighting its potential for applications in cancer research and inflammatory disease studies. -
Antiinflammatory Agent
Ethyl linoleate, an unsaturated fatty acid derivative, acts as an anti-inflammatory agent by inhibiting the Akt/GSK3β/β-catenin signaling pathway and blocking NF-κB activation. Additionally, it induces heme oxygenase-1 and inhibits tyrosinase, contributing to its whitening and anti-inflammatory properties. Ethyl linoleate promotes absorption of compounds and has notable implications for atherosclerosis research. Its applications extend to the study of various inflammatory diseases and cosmetic formulations. -
Anti-inflammatory Reagent
Syringaresinol is a lignan-type phytochemical that primarily targets anti-inflammatory pathways. It effectively inhibits the NF-κB and AKT signaling pathways in IL-1β-activated mouse chondrocytes, demonstrating significant anti-inflammatory activity. Additionally, Syringaresinol enhances the phosphorylation of AMPK and eNOS while increasing intracellular Ca2+ levels in HUVECs. Its ability to attenuate the progression of osteoarthritis in mouse models of DMM-induced osteoarthritis makes it a valuable reagent for research focused on OA. -
Anti-inflammatory/Oxidant
Astringin is a natural flavonoid compound that primarily targets inflammatory pathways and oxidative stress. It exhibits significant anti-inflammatory, antioxidant, and anti-apoptotic activities, while also functioning as a ferroptosis inhibitor. Research applications include its potential use in studying diseases characterized by oxidative damage and inflammation, such as acute lung injury. -
Anti-inflammatory Agent
Strictosamide is a natural compound isolated from Nauclea officinalis, primarily functioning as an anti-inflammatory agent. It exhibits multiple biological activities, including analgesic properties, anti-Plasmodium effects, antifungal activity, and the promotion of wound healing. This compound is valuable for research in inflammation, pain management, and infectious disease studies. -
Inflammatory Modulator
Cholesta-3,5-diene is an inflammatory modulator that primarily targets immune cells, including neutrophils, to enhance wound healing processes. It facilitates neutrophil chemotaxis and fibroblast migration by activating chemokine receptor-mediated signaling pathways, such as the PI3K/Akt pathway. This compound can be utilized in topical applications for wound repair and exhibits potential therapeutic benefits in managing chronic ulcers and skin lesions. -
Anti-Inflammatory/Immunosuppressive Signal
Phosphatidylserine is a phospholipid that serves as an important anti-inflammatory and immunosuppressive signal. It is known to facilitate membrane translocation and activate protein kinase C, which is integral to Akt signaling through its interaction with PIP3. Additionally, localized exposure to phosphatidylserine promotes microglial phagocytosis, aiding in synaptic refinement, and acts as a pro-coagulant factor in the extracellular space by signaling for the clearance of apoptotic cells. This reagent has significant implications in research focused on inflammation regulation and immune response modulation. -
Anti-inflammatory And Antioxidant
Tamarixetin, a 4'-O-Methyl Quercetin derivative, serves as a potent inhibitor of the caseinolytic protease P (ClpP) and exhibits significant anti-inflammatory and antioxidant properties. This natural flavonoid effectively inhibits ClpP's hydrolytic activity towards the substrate Suc-LY-AMC with an IC50 of 49.73 μM, making it relevant for research involving Staphylococcus aureus infections. Additionally, Tamarixetin demonstrates the ability to inhibit tumor cell growth, induce apoptosis, and induce cell cycle arrest, while also preventing cardiac hypertrophy through the modulation of NFAT and AKT signaling pathways. -
Anticancer/Anti-inflammatory/Anti-diabetic Agent
Phellopterin is a furocoumarin compound recognized for its anticancer, anti-inflammatory, and anti-diabetic activities. It functions as a partial agonist of central benzodiazepine receptors and demonstrates significant anti-inflammatory properties by modulating key pathways such as SIRT1 and TLR4/NF-κB, which may aid in conditions like chronic inflammation and atopic dermatitis. Additionally, Phellopterin has been shown to inhibit ovarian cancer progression through the PU.1/CLEC5A/PI3K-AKT signaling loop and promotes adipocyte differentiation, contributing to its anti-diabetic effects. This compound is valuable for research in cancer, inflammation, diabetes management, and antiviral studies. -
Anti-neuroinflammatory Agent
2-O-Methylatromentin is an anti-neuroinflammatory agent that effectively inhibits the production of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, in lipopolysaccharide (LPS)-induced BV-2 microglial cells. This compound is valuable for research into neuroinflammatory diseases, providing insights into the mechanisms underlying inflammation in the central nervous system. Its efficacy in modulating inflammatory responses makes it a useful tool for investigating potential therapeutic strategies in neuroinflammatory conditions. -
TNF Receptor
SYLQDSVPDSFQD is an anchor-modified peptide designed for high-affinity binding to the TNF receptor, specifically DR4. This DR4-restricted MHC class II peptide is utilized in research for studying immune responses and the modulation of TNF-mediated signaling pathways. Its enhanced binding properties make it a valuable tool for investigating therapeutic strategies in inflammation and cancer research. -
COX-2 Inhibitor
Ataquimast is a selective COX-2 inhibitor that effectively suppresses the release of leukotrienes, TNF-α, and GM-CSF. Its mechanism supports research into inflammatory responses and has potential applications in the study of advanced estrogen receptor-positive breast cancer. This compound may aid in elucidating the role of COX-2 in tumor progression and therapeutic resistance. -
Selective Intranasal TLR7 Agonist
GSK2245035 maleate is a selective intranasal agonist of Toll-Like receptor 7 (TLR7), exhibiting potent Type-1 interferon (IFN) stimulating activity with pEC50 values of 9.3 for IFNα and 6.5 for TNFα. This compound effectively reduces allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 maleate is primarily utilized in research focused on asthma and other Th2-mediated allergic responses. -
Anti-inflammatory Agent
Anti-inflammatory Agent 22 is an orally active compound targeting the inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNF-α) production, demonstrated by an IC50 of 14.6 μM. This agent exhibits preventive effects on lymphedematous tissue by suppressing adipogenesis. Additionally, Anti-inflammatory Agent 22 has been shown to reduce limb lymphedema volume in murine models, making it a valuable tool for research into inflammatory conditions and lymphedema management. -
Anti-inflammatory Agent
Anti-inflammatory Agent 15 is a potent compound targeting inflammation through inhibition of nitric oxide synthase (iNOS). It demonstrates significant antimycobacterial activity against Mycobacterium tuberculosis strains H37Rv and M299, with MIC50 values of 2.3 μM and 7.8 μM, respectively. This agent effectively reduces pro-inflammatory cytokines TNF-α and IL-1β, making it a valuable tool for researching tuberculosis and related inflammatory pathways.
